DOP2020000104A - Métodos de uso y composiciones que contienen dulaglutida - Google Patents

Métodos de uso y composiciones que contienen dulaglutida

Info

Publication number
DOP2020000104A
DOP2020000104A DO2020000104A DO2020000104A DOP2020000104A DO P2020000104 A DOP2020000104 A DO P2020000104A DO 2020000104 A DO2020000104 A DO 2020000104A DO 2020000104 A DO2020000104 A DO 2020000104A DO P2020000104 A DOP2020000104 A DO P2020000104A
Authority
DO
Dominican Republic
Prior art keywords
methods
compositions containing
dulaglutida
dulaglutide
doses
Prior art date
Application number
DO2020000104A
Other languages
English (en)
Inventor
San Tham Lai
Gordon Werner Andrew
Bradley Woodward David
Andrew Cox David
Milicevic Zvonko
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2020000104A publication Critical patent/DOP2020000104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a métodos para usar nuevas dosis de dulaglutida y composiciones que contienen dichas dosis más altas de dulaglutida.
DO2020000104A 2017-11-21 2020-06-01 Métodos de uso y composiciones que contienen dulaglutida DOP2020000104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Publications (1)

Publication Number Publication Date
DOP2020000104A true DOP2020000104A (es) 2020-08-31

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000104A DOP2020000104A (es) 2017-11-21 2020-06-01 Métodos de uso y composiciones que contienen dulaglutida

Country Status (20)

Country Link
US (1) US11576950B2 (es)
EP (1) EP3713593A2 (es)
JP (3) JP7221956B2 (es)
KR (2) KR102589234B1 (es)
CN (1) CN111356472A (es)
AU (2) AU2018372709B2 (es)
BR (1) BR112020007817A2 (es)
CA (1) CA3082625A1 (es)
CL (1) CL2020001252A1 (es)
CR (1) CR20200202A (es)
DO (1) DOP2020000104A (es)
EA (1) EA202090971A1 (es)
EC (1) ECSP20026436A (es)
IL (1) IL274563B2 (es)
JO (1) JOP20200126A1 (es)
MA (1) MA50798A (es)
MX (1) MX2020005231A (es)
SG (1) SG11202003687RA (es)
UA (1) UA127588C2 (es)
WO (1) WO2019103875A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1724284T3 (da) 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
WO2005000892A2 (en) 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations
AU2008275180A1 (en) * 2007-07-10 2009-01-15 Eli Lilly And Company GLP-1-Fc fusion protein formulation
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US20200171129A1 (en) 2017-06-01 2020-06-04 Eli Lilly And Company Therapeutic uses of dulaglutide

Also Published As

Publication number Publication date
JP7221956B2 (ja) 2023-02-14
JOP20200126A1 (ar) 2020-05-21
MX2020005231A (es) 2020-08-24
AU2022203372A1 (en) 2022-06-09
CL2020001252A1 (es) 2020-10-30
BR112020007817A2 (pt) 2020-10-06
IL274563B1 (en) 2023-08-01
SG11202003687RA (en) 2020-06-29
IL274563A (en) 2020-06-30
KR20200076705A (ko) 2020-06-29
JP2021502379A (ja) 2021-01-28
JP2022062153A (ja) 2022-04-19
MA50798A (fr) 2020-09-30
CA3082625A1 (en) 2019-05-31
WO2019103875A3 (en) 2019-07-25
JP2024056908A (ja) 2024-04-23
WO2019103875A2 (en) 2019-05-31
US20200330558A1 (en) 2020-10-22
AU2018372709A1 (en) 2020-05-14
ECSP20026436A (es) 2020-06-30
IL274563B2 (en) 2023-12-01
EP3713593A2 (en) 2020-09-30
AU2018372709B2 (en) 2022-04-28
US11576950B2 (en) 2023-02-14
EA202090971A1 (ru) 2020-08-07
KR102589234B1 (ko) 2023-10-16
CR20200202A (es) 2020-08-20
UA127588C2 (uk) 2023-10-25
CN111356472A (zh) 2020-06-30
KR20220146656A (ko) 2022-11-01
NZ763815A (en) 2023-11-24

Similar Documents

Publication Publication Date Title
CO2020007244A2 (es) Inhibidores de kras g12c
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
CR20160419A (es) Nuevos compuestos biciclicos
SV2017005471A (es) Derivados de quinazolina utilizados para tratar el vih
SV2018005778A (es) Derivados aromaticos de sulfonamida
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
UY36759A (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
BR112017027132A2 (pt) reguladores do nrf2
BR112017027137A2 (pt) reguladores de nrf2
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112018071048A2 (pt) combinações e métodos que compreendem um inibidor da montagem de capsídeos
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
UY36602A (es) Variantes de protoxina-ii y métodos de uso
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
BR112017002090A2 (pt) formulação de fator viii
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio